Clinical Trials Logo

HER2-positive Breast Cancer clinical trials

View clinical trials related to HER2-positive Breast Cancer.

Filter by:

NCT ID: NCT00817362 Terminated - Breast Cancer Clinical Trials

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer

NCT ID: NCT00079326 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Start date: January 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving trastuzumab together with ixabepilone works in treating women with HER2-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with ixabepilone may kill more tumor cells.

NCT ID: NCT00039455 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flavopiridol may kill more tumor cells. Phase I trial to study the effectiveness of combining trastuzumab with flavopiridol in treating patients who have metastatic breast cancer